Related Experiment Video

Updated: Jun 2, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation

Claudia Penafuerte1, Norma Bautista-Lopez, Manaf Bouchentouf

  • 1Department of Experimental Medicine, McGill University, Montreal, Quebec H3A 1A3, Canada.

Journal of Immunology (Baltimore, Md. : 1950)
|May 10, 2011
PubMed

Insights

A novel chimeric protein, FIST, combines IL-2 and TGF-βRII to block tumor-promoting TGF-β and activate anti-cancer immunity. This approach effectively inhibits tumor growth by enhancing natural killer cell responses.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Tumor-derived transforming growth factor-beta (TGF-β) promotes cancer progression by suppressing antitumor immunity.
  • Developing strategies to counteract TGF-β's immunosuppressive effects is crucial for effective cancer therapy.

Purpose of the Study:

  • To develop a novel therapeutic agent, FIST (fusion of IL-2 and TGF-βRII extracellular domain), to antagonize TGF-β and stimulate antitumor immunity.
  • To investigate the mechanisms by which FIST enhances anti-cancer immune responses and inhibits tumor growth.

Main Methods:

  • Generation of a chimeric protein (FIST) by fusing IL-2 with the soluble extracellular domain of TGF-β receptor II.
  • In vitro and in vivo studies using cancer cell lines (PANC02, B16) and immunocompetent/deficient mouse models.
  • Analysis of immune cell activation, cytokine production, gene expression (STAT1, SMAD7, T-bet), and tumor growth inhibition.

Main Results:

  • FIST acts as a decoy receptor, trapping active TGF-β and preventing its immunosuppressive effects.
  • FIST induces STAT1 hyperactivation in lymphoid cells, leading to SMAD7 overexpression and resistance to TGF-β.
  • FIST promotes proinflammatory cytokine secretion, upregulates T-bet in NK cells, and significantly inhibits pancreatic cancer and melanoma growth in mice.
  • Tumor inhibition is dependent on NK cells, CD4+, and CD8+ T cells, highlighting the role of innate and adaptive immunity.

Conclusions:

  • FIST represents a novel bifunctional therapeutic strategy targeting both TGF-β signaling and host immune responses.
  • FIST effectively stimulates innate and adaptive antitumor immunity, leading to complete tumor growth inhibition in preclinical models.
  • This approach holds promise for treating various cancers by overcoming immunosuppression and enhancing the host's immune defense against tumors.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System11:06

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

Published on: July 30, 2018

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.